Donggeng Liu
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: December 28, 2021
Development and validation of a nomogram in survival prediction among advanced breast cancer patients.
Journal: Annals of translational medicine
Published: December 14, 2020
Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.
Journal: Japanese journal of clinical oncology
Published: May 13, 2020
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
Journal: Cancer
Published: September 01, 2019
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Journal: Breast cancer research : BCR
Published: July 25, 2016
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Journal: Oncotarget
Published: February 03, 2016
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Journal: The Lancet. Oncology
Published: March 19, 2015
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
Journal: OncoTargets and therapy
Published: May 01, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026